This program reviews evidence-based guidance on the use of tyrosine kinase inhibitors (TKIs) in the management of chronic myeloid leukemia (CML). The introduction of TKIs has transformed CML management and dramatically improved patient survival. With the survival advantage conferred by TKIs, the careful consideration of parameters such as safety and tolerability of TKIs is important, as many patients remain on treatment for life. Management of adverse events remains critical to ensuring adherence to treatment, maintenance of efficacy and overall quality of life.
This program has received an unrestricted educational grant or in-kind support from Pfizer.